Please assess the completion status of the following clinical trial:

Trial Title: Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of ITP ≥6 months;Platelets \<30×109/L.~2. No evidence of other causes of thrombocytopenia.~3. Subjects who are refractory or have relapsed after at least one prior ITP therapy.~4. Previous therapy for ITP including rescue must have been completed at least 2 weeks prior to randomization.~5. Subjects treated with maintenance immunosuppressive therapy must be receiving a dose that has been stable for at least 1 month.~6. PT result no exceed normal by more than ±3s,APTT result no exceed normal by more than ±10s.~7. Signed informed consent.~Exclusion Criteria:~1. Patients with any prior history of arterial or venous thrombosis，or diagnosis as Thrombophilia.~2. Subjects diagnosed with tumor.~3. Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) \>450msec or QTc \>480 for patients with a Bundle Branch Block.~4. Female subjects who are nursing or pregnant at screening or pre-dose on baseline.~5. Subjects who have previously received eltrombopag or any other thrombopoietin receptor agonist within 30 days .~6. Subject has consumed aspirin, aspirin-containing compounds, salicylates, anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for \>3 consecutive days within 2 weeks of the study start and until the end of the study.~7. Any laboratory or clinical evidence for HIV infection.Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening.~8. ALT\> 1.5 x upper limit of normal (ULN), AST\> 3 x upper limit of normal (ULN)) DBLI\> 1.2 x upper limit of normal (ULN),Scr\> 1.2 x upper limit of normal (ULN)~9. The subject has participated in other clinical trial within the 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): oral hetrombopag at an initial dose of 2.5 mg once daily
- Arm 2 (Type: EXPERIMENTAL): oral hetrombopag at an initial dose of 5 mg once daily
- Arm 3 (Type: PLACEBO_COMPARATOR): oral placebo at an initial dose of 2.5 mg once daily
- Arm 4 (Type: PLACEBO_COMPARATOR): oral placebo at an initial dose of 5 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).